Tharimmune, Inc. announced on October 30, 2024, that it received positive feedback from a Scientific Advice meeting with the European Medicines Agency (EMA). This feedback pertained to the clinical program for TH104, its lead clinical-stage candidate.
The EMA provided guidance on the planned Phase 2 and Phase 3 clinical program of TH104 for moderate-to-severe pruritus in primary biliary cholangitis (PBC). This regulatory clarity is crucial for advancing the development of TH104 in Europe.
The positive interaction with the EMA helps to define the regulatory pathway for TH104, supporting the company's efforts to bring this therapeutic candidate to patients suffering from chronic pruritus associated with PBC.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.